Plexiform Neurofibroma Treatment Global Market Report 2025

The plexiform neurofibroma treatment market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. This historical growth was driven by a rising incidence of neurofibromatosis type 1, enhanced global awareness and diagnostic efforts for plexiform neurofibroma, increased R&D funding from pharmaceutical firms, an expanding portfolio of promising drug candidates in clinical stages, and improvements in healthcare infrastructure.

The plexiform neurofibroma treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this projected growth include rising health expenditures, stronger government support for rare disease therapies, greater involvement of patient advocacy groups spreading awareness, increasing interest in non-invasive treatment methods, and a growing inclination toward oral medications over surgical approaches. Notable trends during the forecast period include breakthroughs in molecular biology supporting targeted treatments, greater use of sophisticated imaging tools for early diagnosis, development of new small-molecule drugs aimed at specific signaling pathways, progress in biotechnology promoting antibody-based solutions, and advancements in biomarker discovery for tracking disease evolution.

The growing demand for personalized medicine is anticipated to drive the expansion of the plexiform neurofibroma treatment market. Personalized medicine is a healthcare approach that tailors medical treatment based on an individual’s genetic profile, biological characteristics, and personal health data. This approach enhances treatment effectiveness by aligning therapies with a patient’s specific genetic and biological profile, resulting in improved outcomes and reduced side effects. As the need for personalized medicine increases, it supports the development of tailored therapeutic strategies for plexiform neurofibroma, addressing unique genetic mutations and tumor behaviors in each patient. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that 12 new personalized medicines received approval in 2022, accounting for approximately 34% of all newly approved therapies, marking a significant rise from previous years. Consequently, the rising demand for personalized medicine is fueling growth in the plexiform neurofibroma treatment market.

Leading companies in the plexiform neurofibroma treatment market are emphasizing the development of advanced treatments, such as small-molecule inhibitors, to improve therapeutic outcomes. Small-molecule inhibitors are low-molecular-weight compounds designed to interfere with specific proteins or enzymes to disrupt abnormal cellular activities. For instance, in February 2025, SpringWorks Therapeutics, a US-based biopharmaceutical firm, announced FDA approval for Gomekli, an oral small-molecule MEK inhibitor. Gomekli is approved for use in adults and children aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that are not surgically resectable. Clinical trials revealed that 41% of adults and 52% of pediatric patients experienced confirmed tumor size reduction, with average tumor volume decreasing by 41% in adults and 42% in children. Furthermore, responses lasting at least 12 months were observed in 88% of adults and 90% of children, with nearly half of all patients in both groups maintaining their response for over 24 months.

In April 2025, Merck Group, a Germany-based pharmaceutical company, acquired SpringWorks Therapeutics for $3.4 billion. The acquisition is aimed at immediately boosting Merck’s healthcare revenues, accelerating its mid- to long-term growth, and enhancing its presence in the U.S. market. This strategic move broadens Merck’s portfolio in rare tumors and rare diseases, as SpringWorks contributes two FDA-approved treatments - Ogsiveo for desmoid tumors and Gomekli for neurofibromatosis type 1-associated plexiform neurofibromas. SpringWorks Therapeutics is a U.S.-based biopharmaceutical company specializing in treatments for plexiform neurofibroma.

Major players in the plexiform neurofibroma treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceuticals Industries Limited, Aurobindo Pharma, Amneal Pharmaceuticals LLC, Endo Pharmaceuticals Inc., Exelixis Inc., Mallinckrodt Plc, SpringWorks Therapeutics, Sangamo Therapeutics Inc., Recursion Pharmaceuticals Inc., Noveome Biotherapeutics Inc., and BioXcel Therapeutics Inc.

North America was the largest region in the plexiform neurofibroma treatment market in 2024. The regions covered in plexiform neurofibroma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plexiform neurofibroma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plexiform neurofibroma treatment encompasses medical strategies designed to manage and control the growth of complex nerve sheath tumors. The primary aim is to alleviate symptoms, avoid complications, and enhance the quality of life by addressing the tumor’s effects on adjacent tissues and structures.

Key treatment options for plexiform neurofibroma include surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is a medical discipline that involves treating injuries, illnesses, or other conditions using manual and instrumental techniques, typically by performing incisions to remove, repair, or examine internal tissues or organs. It is utilized for various purposes such as alleviating pain, reducing tumor size, and restoring function in both children and adults. These procedures are carried out across diverse settings, including hospitals, clinics, and home care environments.

The plexiform neurofibroma treatment market research report is one of a series of new publications that provides plexiform neurofibroma treatment market statistics, including global market size, regional distributions, key competitors by market share, in-depth market segmentation, emerging trends, opportunities, and all other essential insights to succeed in the plexiform neurofibroma treatment industry. This market research report offers a comprehensive overview and detailed evaluation of the current and projected industry landscape.

The plexiform neurofibroma treatment market consists of revenues earned by entities by providing services such as genetic testing, clinical evaluation, multidisciplinary care coordination, and clinical trial management. The market value includes the value of related goods sold by the service provider or included within the service offering. The plexiform neurofibroma treatment market also includes sales of tumor monitoring kits, genetic testing kits, clinical decision support tools, and rehabilitation aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.